Zhimin  Hu Hu

Dr. Zhimin Hu Hu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RTRui Tang
Rui Tang
YJYue Jian
Yue Jian
ZHZhimin Hu Hu
Zhimin Hu Hu
LLLi Li
Li Li
HWHaitao Wang
Haitao Wang
MTMingxi Tang
Mingxi Tang
Alzheimer’s disease (AD) is characterized by progressive cognitive decline and late-stage neurobehavioral issues marked by amyloid-beta plaques and Tau protein tangles. This study aims to investigate Fibulin-1(FBLN1) gene expression in the hippocampal tissue of Presenilin-1/Presenilin-2 conditional double-knockout (DKO) and double-transgenic (DTG) mice, using single-cell sequencing and experimental methods to verify abnormal methylation status and correlation with AD. Genomic DNA from DKO and DTG mice was used for genotyping. Reduced Representation Bisulfite Sequencing (RRBS) identified 10 genes with abnormal methylation changes, with protein–protein interaction (PPI) analysis highlighting five core genes, including FBLN1. Single-cell sequencing, RT-PCR, and Western blotting (WB) were used to analyze FBLN1 mRNA and protein levels in the hippocampal tissues of early-stage and mid-stage AD DKO, DTG, and CBAC57 mice. RRBS identified 10 genes with abnormal methylation, with PPI highlighting five core genes. Single-cell sequencing showed significant FBLN1 expression in AD groups. RT-PCR and WB indicated elevated FBLN1 mRNA and protein levels in mid-stage AD DKO and DTG mice compared to CBAC57 mice, with no differences in early-stage AD DKO and CBAC57 mice. RRBS revealed hypomethylation of the FBLN1 gene in mid-stage AD DKO mice. Elevated FBLN1 expression in AD models suggests an age-dependent neurodegenerative mechanism independent of amyloid-beta deposition. This study enhances our understanding of AD’s epigenetic mechanisms, which will aid targeted diagnosis, treatment, and prognosis.

1 February 2026 in Breast Cancer: Targets and Therapy
Verified
Journal Article
Open access
RYRupei Ye
Rupei Ye
XDXinzhi Dai
Xinzhi Dai
ZYZihan Yang
Zihan Yang
DZDandan Zhang
Dandan Zhang
ZHZhimin Hu Hu
Zhimin Hu Hu
YZYang ZhiHui
Yang ZhiHui
Metaplastic breast carcinoma (MBC) is a rare and aggressive subtype of triple-negative breast cancer with distinct molecular features that remain incompletely characterized, hindering the development of effective therapies. We integrated clinicopathological data with next-generation sequencing (NGS) of 437 cancer-related genes performed on 25 tumor samples (16 primary, 8 lymph node metastases, 1 distant metastasis) from 17 MBC patients. Functional enrichment analysis was conducted to identify key signaling pathways. Recurrent alterations were identified in TP53 (14/16, 87.5%), PIK3CA (9/16, 56.2%), and MCL1 (10/16, 62.5% amplified). TP53 mutations (primarily frameshift and missense) showed consistent variant types between primary and metastatic sites. PIK3CA hotspot mutations (eg, H1047R, E545K) persisted across metastases. In contrast, MCL1 amplification exhibited dynamic evolution, being lost in some primary tumors but acquired de novo in lymph node metastases. Functional enrichment analysis revealed the PI3K-Akt signaling pathway as the most significantly altered pathway in MBC. This study delineates the distinct mutational landscape and clonal evolution patterns of MBC, underpinned by truncal mutations in TP53 and PIK3CA alongside dynamic MCL1 amplification. The persistent activation of the PI3K-Akt pathway presents a key therapeutic vulnerability. Our findings emphasize the potential of PI3K-Akt inhibition and metastasis-specific targeting strategies for this aggressive disease.